International Journal of Toxicology
Published in Association with American College of Toxicology
eISSN:
1092874X | ISSN:
10915818 | Current volume: 43 | Current issue: 6
Frequency: Bi-monthly
International Journal of Toxicology (IJT) offers academic, industry, and regulatory toxicologists, as well as toxicology consultants, timely, peer-reviewed, multidisciplinary articles and incisive reviews on contemporary issues in toxicology, plus safety assessments, novel approaches to toxicological testing, mechanisms of toxicity, biomarkers, and risk assessment. Each issue of IJT provides an important forum for articles that promote basic toxicology research, as well as those that facilitate and improve toxicology practice.
We are currently seeking manuscript submissions in these (and related) areas:
• Advances in drug development
• Safety assessments
• New therapeutic targets
• Alternatives/refinement to use of animals in toxicology
• Target organ toxicology
• Immunotoxicology testing advances/challenges
• Regulatory issues
• New approaches to toxicological testing
and data interpretation
• Risk assessment advances
• Biomarkers of toxicity
• Mechanisms of toxicology
IJT also publishes invited reviews, articles based on symposia, book and media reviews, and editorials. IJT publishes sponsored supplemental issues, including four issues each year devoted to contributions from the Cosmetic Ingredient Review Expert Panel.
International Journal of Toxicology, the official journal of the American College of Toxicology (ACT), welcomes contributions from authors, reviewers, and Editorial Board members from all backgrounds, and supports aspiring and established toxicology professionals. ACT is committed to diversity, equity, and inclusion (DEI) within our organization. We strive to empower individuals to actively engage, collaborate, and exchange ideas, and we embrace diversity in expression, perspective, and experience.
Submit your manuscript today at https://mc.manuscriptcentral.com/uito
We are currently seeking manuscript submissions in these (and related) areas:
• Advances in drug development
• Safety assessments
• New therapeutic targets
• Alternatives/refinement to use of animals in toxicology
• Target organ toxicology
• Immunotoxicology testing advances/challenges
• Regulatory issues
• New approaches to toxicological testing
and data interpretation
• Risk assessment advances
• Biomarkers of toxicity
• Mechanisms of toxicology
IJT also publishes invited reviews, articles based on symposia, book and media reviews, and editorials. IJT publishes sponsored supplemental issues, including four issues each year devoted to contributions from the Cosmetic Ingredient Review Expert Panel.
International Journal of Toxicology, the official journal of the American College of Toxicology (ACT), welcomes contributions from authors, reviewers, and Editorial Board members from all backgrounds, and supports aspiring and established toxicology professionals. ACT is committed to diversity, equity, and inclusion (DEI) within our organization. We strive to empower individuals to actively engage, collaborate, and exchange ideas, and we embrace diversity in expression, perspective, and experience.
Submit your manuscript today at https://mc.manuscriptcentral.com/uito
International Journal of Toxicology (IJT) offers academic, industry, and regulatory toxicologists, as well as toxicology consultants, timely, peer-reviewed, multidisciplinary articles and incisive reviews on contemporary issues in toxicology, plus safety assessments, novel approaches to toxicological testing, mechanisms of toxicity, biomarkers, and risk assessment. Each issue of IJT provides an important forum for articles that promote basic toxicology research, as well as those that facilitate and improve toxicology practice.
IJT also publishes invited reviews, articles based on symposia, book and media reviews, and editorials. IJT publishes sponsored supplemental issues, including four issues each year devoted to contributions from the Cosmetic Ingredient Review Expert Panel.
Editor
| Mary Beth Genter, PhD | University of Cincinnati, USA |
Associate Editors
| Bruce K. Bernard, PhD | SRA Consulting, Cambridge, MD, USA |
| Marion F. Ehrich, PhD | VA-MD Regional College of Veterinary Medicine, Blacksburg, VA, USA |
| Donald G. Stump, PhD | Charles River, Ashland, OH, USA |
Book Review Editor
| Robert W. Kapp, Jr., PhD | BioTox, Stafford Township, NJ, USA |
Editors Emeriti
Editorial Board
| Krishna P. Allamneni, PhD | Concarlo Therapeutics, Inc., Brooklyn, NY, USA |
| Shana Azri-Meehan, PhD | Cardinal Health, Millington, NJ, USA |
| Theodore J. Baird, PhD | Charles River, Mattawan, MI, USA |
| Lisa D. Beilke, PhD | Toxicology Solutions, Inc., San Diego, CA, USA |
| Susan Borghoff, PhD | ToxStrategies, Inc., Cary, NC, USA |
| William J. Brock, PhD | Brock Scientific Consulting, Montgomery, MD |
| Alan P. Brown, PhD | Novartis Institutes for BioMedical Research, Cambridge, MA, USA |
| Lorrene A. Buckley, PhD | Eli Lilly and Company, Indianapolis, IN, USA |
| John A. Budny, PhD | PharmaCal, Redding, CA, USA |
| Florence G. Burleson, PhD | BRT-Burleson Research Technologies, Inc., Morrisville, NC, USA |
| Gary R. Burleson, PhD | BRT-Burleson Research Technologies, Inc., Morrisville, NC, USA |
| Leigh Ann Burns Naas, PhD | Magnolia Toxicology Consulting, LLC, Traverse City, MI, USA |
| Erica Carroll, DVM, PhD | Covance, Greenfield, IN, USA |
| Charleata Carter, PhD | Carter Consulting, Greensboro, NC, USA |
| Scott Coleman, PhD | Acceleron, Attleboro, MA, USA |
| David Compton, PhD | Annandale, NJ, USA |
| Mary Ellen Cosenza, MEC | Regulatory & Toxicology Consulting, LLC, Moorpark, CA, USA |
| Matthew Z. Dieter, PhD | Eli Lilly and Company, Indianapolis, IN, USA |
| Sandy Eldridge, PhD | National Cancer Institute, NIH, Bethesda, MD, USA |
| Li-jie Fu, PhD | Shin Nippon Biomedical Labs, Ltd, Beijing, China |
| Shayne C. Gad, PhD | Gad Consulting Services, Cary, NC, USA |
| Hanan N. Ghantous, PhD | US FDA, Silver Spring, MD, USA |
| Robin C. Guy, MS | Robin Guy Consulting, LLC, Lake Forest, IL, USA |
| Bert Haenen, PhD | Janssen Research and Development, Beerse, Belgium |
| Jerry F. Hardisty | EPL Inc., Research Triangle Park, NC, USA |
| Stephen B. Harris, PhD | Stephen B. Harris Group, San Diego, CA, USA |
| Kenneth L. Hastings, DrPH | Hastings Toxicology Consulting, LLC, Mount Airy, MD, USA |
| Alan M. Hoberman, PhD | Charles River, Horsham, PA, USA |
| David W. Hobson, PhD | LoneStar PharmTox LLC, Boerne, TX, USA |
| Debie Hoivik, PhD | Akebia Therapeutics, Cambridge, MA, USA |
| Heidi Hsieh, PhD | Covance, Madison, WI, USA |
| Elaine V. Knight, PhD | National Cancer Institute, NIH, Bethesda, MD, USA |
| Stephen B. Montgomery, PhD | Consulting Nonclinical Safety Assessment, Alpharetta, GA, USA |
| P. Balakrishna Murthy, PhD, DSc | Consultant Toxicologist, Chennai, India |
| Kenneth J. Olivier, Jr., PhD | Morphic Therapeutics, Attleboro, MA, USA |
| Madhav Paranjpe, DVM, PhD | Charles River, Mattawan, MI, USA |
| Charles W. Qualls, Jr., DVM, PhD | Thousand Oaks, California, USA |
| Gunda Reddy, PhD | Fallston, MD, USA |
| Robert Roy, PhD | Northland Toxicology Consultants, LLC, MN, USA |
| Alan H. Stokes, PhD | GSK, Rockville, MD, USA |
| Tao Wang, MD, PhD | Coherus BioSciences, Redwood City, CA, USA |
| Adam Woolley, MSc, FRCPath | ForthTox Ltd., Linlithgow, Scotland, UK |
| David Woolley, PhD | Forthtox, Ltd., Linlithgow, Scotland |
Manuscript submission guidelines can be accessed on Sage Journals.